Today, global family blood glucose management expert Johnson & Johnson Medical announced that it has joined hands with JD.com to achieve strategic cooperation to jointly promote the exploration of chronic disease management such as diabetes based on big data. As the first step of this cooperation, Johnson & Johnson's first full-color smart home blood glucose meter - Johnson & Johnson, Stable and Smart, was launched in Jingdong today. Mr. Amechi Nwachuku, Vice President of Johnson & Johnson Medical Europe, Middle East Africa and Asia Pacific, said that “Johnson Medical has been actively involved in chronic disease management and mobile healthcare . Jingdong Pharmaceutical Health is a leading retail channel in China's pharmaceutical health, with strong brand influence and quality. The customer group has also actively explored the management of chronic diseases, which coincides with the development strategy of Johnson & Johnson Medical. We are very pleased to join hands with JD, to explore cooperation in diabetes management and even mobile medicine, and jointly promote China. The development of chronic disease management."
Working together with strategic cooperation - exploring new prospects for chronic disease management based on big data
Diabetes is the number one chronic disease in China. According to the statistics of the International Diabetes Federation, in 2015, China's diabetes patients ranked first in the world, reaching 110 million, that is, every ten Chinese have a diabetes-related disease. The number of deaths due to diabetes exceeds 1 million per year. At the same time, diabetes is also prone to various complications such as cardiovascular disease, renal failure, and vision deterioration. With the progress of aging, the number of diabetic patients in China is constantly rising. How to effectively manage daily blood sugar has gradually become a serious problem.
In order to better promote the sustainable development of China's big health industry, Johnson & Johnson and JD.com have reached a strategic cooperation. We hope to use this latest blood glucose meter as an opportunity to jointly promote diabetes management based on big data and explore the future of mobile medical care. A new model of development. Wei Kai, general manager of Jingdong Pharmaceutical Health, said: "As the consumption of health industry upgrades, consumers' demand for high-quality products and services continues to increase. The launch of Wenyue Zhiyou Glucose Meter in Jingdong is the first step of our strategic cooperation. In the future, both of us will have more in-depth cooperation in mobile medical and chronic disease management."
Antitumor And Chemotherapy Antiemetic
Antitumor And Chemotherapy Antiemetic,Tropisetron Hydrochloride Tablets,Tablets Of Tropisetron Hydrochloride,Tablets For Antitumor And Antiemetic
Shandong Qidu Pharmaceutical Co., Ltd. , https://www.qdyypharma.com